Literature DB >> 29497922

Why Patients Decline Genomic Sequencing Studies: Experiences from the CSER Consortium.

Laura M Amendola1, Jill O Robinson2, Ragan Hart3, Sawona Biswas4,5, Kaitlyn Lee2, Barbara A Bernhardt5, Kelly East6, Marian J Gilmore7, Tia L Kauffman8, Katie L Lewis9, Myra Roche10, Sarah Scollon11, Julia Wynn12, Carrie Blout13.   

Abstract

Clinical and research settings are increasingly incorporating genomic sequencing (GS) technologies. Previous research has explored reasons for declining genetic testing and participation in genetic studies; however, there is a dearth of literature regarding why potential participants decline participation in GS research, and if any of these reasons are unique to GS. This knowledge is essential to promote informed decision-making and identify potential barriers to research participation and clinical implementation. We aggregated data from seven sites across the National Institutes of Health's Clinical Sequencing Exploratory Research (CSER) consortium on each project's procedures for recruitment, and rates of and reasons for decline. Data were analyzed using descriptive statistics. The decline rate for enrollment at the seven CSER sites ranged from 12 to 64% (median 28%) and varied based on age and disease status. Projects differed in their protocols for approaching potential participants and obtaining informed consent. Reasons for declining GS research were reported for 1088 potential participants. Commonly cited reasons were similar to those reported for clinical single gene testing and non-GS genetic research. The most frequently cited reason for decline was study logistics (35%); thus, addressing logistical barriers to enrollment may positively impact GS study recruitment. Privacy and discrimination concerns were cited by 13% of decliners, highlighting the need for researchers and providers to focus educational efforts in this area. The potential psychological burden of pursuing and receiving results from GS and not wanting to receive secondary findings, a concern specific to GS, have been cited as concerns in the literature. A minority of potential participants cited psychological impact (8%) or not wanting to receive secondary findings (2%) as reasons for decline, suggesting that these concerns were not major barriers to participation in these GS studies. Further research is necessary to explore the impact, if any, of different participant groups or study protocols on rates of decline for GS studies. Future studies exploring GS implementation should consider using standardized collection methods to examine reasons for decline in larger populations and more diverse healthcare settings.

Entities:  

Keywords:  Clinical Sequencing Exploratory Research (CSER) consortium; Exome sequencing; Genome sequencing; Rate of decline; Reason for decline

Mesh:

Year:  2018        PMID: 29497922      PMCID: PMC6119550          DOI: 10.1007/s10897-018-0243-7

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  32 in total

Review 1.  Public willingness to participate in and public opinions about genetic variation research: a review of the literature.

Authors:  Rene Sterling; Gail E Henderson; Giselle Corbie-Smith
Journal:  Am J Public Health       Date:  2006-10-03       Impact factor: 9.308

2.  The right not to know and preimplantation genetic diagnosis for Huntington's disease.

Authors:  E Asscher; B-J Koops
Journal:  J Med Ethics       Date:  2010-01       Impact factor: 2.903

3.  GINA, genetic discrimination, and genomic medicine.

Authors:  Robert C Green; Denise Lautenbach; Amy L McGuire
Journal:  N Engl J Med       Date:  2015-01-29       Impact factor: 91.245

4.  Large, Prospective Analysis of the Reasons Patients Do Not Pursue BRCA Genetic Testing Following Genetic Counseling.

Authors:  Sommer Hayden; Sarah Mange; Debra Duquette; Nancie Petrucelli; Victoria M Raymond
Journal:  J Genet Couns       Date:  2017-01-16       Impact factor: 2.537

5.  Engagement with genetic discrimination: concerns and experiences in the context of Huntington disease.

Authors:  Yvonne Bombard; Elizabeth Penziner; Oksana Suchowersky; Mark Guttman; Jane S Paulsen; Joan L Bottorff; Michael R Hayden
Journal:  Eur J Hum Genet       Date:  2007-10-24       Impact factor: 4.246

6.  Non-uptake of predictive genetic testing for BRCA1/2 among relatives of known carriers: attributes, cancer worry, and barriers to testing in a multicenter clinical cohort.

Authors:  C Foster; D G R Evans; R Eeles; D Eccles; S Ashley; L Brooks; T Cole; J Cook; R Davidson; H Gregory; J Mackay; P J Morrison; M Watson
Journal:  Genet Test       Date:  2004

7.  Strategies for enrollment of African Americans into cancer genetic studies.

Authors:  Altovise Ewing; Nicole Thompson; Luisel Ricks-Santi
Journal:  J Cancer Educ       Date:  2015-03       Impact factor: 2.037

8.  Patient decisions for disclosure of secondary findings among the first 200 individuals undergoing clinical diagnostic exome sequencing.

Authors:  Layla Shahmirzadi; Elizabeth C Chao; Erika Palmaer; Melissa C Parra; Sha Tang; Kelly D Farwell Gonzalez
Journal:  Genet Med       Date:  2013-10-10       Impact factor: 8.822

9.  Obtaining informed consent for clinical tumor and germline exome sequencing of newly diagnosed childhood cancer patients.

Authors:  Sarah Scollon; Katie Bergstrom; Robin A Kerstein; Tao Wang; Susan G Hilsenbeck; Uma Ramamurthy; Richard A Gibbs; Christine M Eng; Murali M Chintagumpala; Stacey L Berg; Laurence B McCullough; Amy L McGuire; Sharon E Plon; D Williams Parsons
Journal:  Genome Med       Date:  2014-09-17       Impact factor: 11.117

Review 10.  Stakeholder views on secondary findings in whole-genome and whole-exome sequencing: a systematic review of quantitative and qualitative studies.

Authors:  Michael P Mackley; Benjamin Fletcher; Michael Parker; Hugh Watkins; Elizabeth Ormondroyd
Journal:  Genet Med       Date:  2016-09-01       Impact factor: 8.822

View more
  13 in total

1.  The Clinical Sequencing Evidence-Generating Research Consortium: Integrating Genomic Sequencing in Diverse and Medically Underserved Populations.

Authors:  Laura M Amendola; Jonathan S Berg; Carol R Horowitz; Frank Angelo; Jeannette T Bensen; Barbara B Biesecker; Leslie G Biesecker; Gregory M Cooper; Kelly East; Kelly Filipski; Stephanie M Fullerton; Bruce D Gelb; Katrina A B Goddard; Benyam Hailu; Ragan Hart; Kristen Hassmiller-Lich; Galen Joseph; Eimear E Kenny; Barbara A Koenig; Sara Knight; Pui-Yan Kwok; Katie L Lewis; Amy L McGuire; Mary E Norton; Jeffrey Ou; Donald W Parsons; Bradford C Powell; Neil Risch; Mimsie Robinson; Christine Rini; Sarah Scollon; Anne M Slavotinek; David L Veenstra; Melissa P Wasserstein; Benjamin S Wilfond; Lucia A Hindorff; Sharon E Plon; Gail P Jarvik
Journal:  Am J Hum Genet       Date:  2018-09-06       Impact factor: 11.025

2.  Motivations and concerns of patients considering participation in an implementation study of a hereditary cancer risk assessment program in diverse primary care settings.

Authors:  Devan M Duenas; Kelly J Shipman; Kathryn M Porter; Elizabeth Shuster; Claudia Guerra; Ana Reyes; Tia L Kauffman; Jessica Ezzell Hunter; Katrina A B Goddard; Benjamin S Wilfond; Stephanie A Kraft
Journal:  Genet Med       Date:  2021-11-23       Impact factor: 8.822

3.  Return of individual research results from genomic research: A systematic review of stakeholder perspectives.

Authors:  Danya F Vears; Joel T Minion; Stephanie J Roberts; James Cummings; Mavis Machirori; Mwenza Blell; Isabelle Budin-Ljøsne; Lorraine Cowley; Stephanie O M Dyke; Clara Gaff; Robert Green; Alison Hall; Amber L Johns; Bartha M Knoppers; Stephanie Mulrine; Christine Patch; Eva Winkler; Madeleine J Murtagh
Journal:  PLoS One       Date:  2021-11-08       Impact factor: 3.240

4.  Genetic testing and insurance implications: Surveying the US general population about discrimination concerns and knowledge of the Genetic Information Nondiscrimination Act (GINA).

Authors:  Anya E R Prince; Wendy R Uhlmann; Sonia M Suter; Aaron M Scherer
Journal:  Risk Manag Insur Rev       Date:  2021-11-19

5.  A roadmap for precision medicine research recruitment: empirical assessment of the public's willingness to participate.

Authors:  Kelsey Moriarty; Susan M Wolf; Patricia M Veach; Bonnie LeRoy; Ian M MacFarlane; Heather A Zierhut
Journal:  Per Med       Date:  2020-08-17       Impact factor: 2.512

6.  Evaluation of the cost and effectiveness of diverse recruitment methods for a genetic screening study.

Authors:  Hila Milo Rasouly; Julia Wynn; Maddalena Marasa; Rachel Reingold; Debanjana Chatterjee; Sheena Kapoor; Stacy Piva; Byum Hee Kil; Xueru Mu; Maria Alvarez; Jordan Nestor; Karla Mehl; Anya Revah-Politi; Natalie Lippa; Michelle E Ernst; Louise Bier; Aileen Espinal; Bianca Haser; Anoushka Sinha; Ian Halim; David Fasel; Nicole Cuneo; Jacqueline J Thompson; Miguel Verbitsky; Elizabeth G Cohn; Jill Goldman; Karen Marder; Robert L Klitzman; Manuela A Orjuela; Yat S So; Alex Fedotov; Katherine D Crew; Krzysztof Kiryluk; Paul S Appelbaum; Chunhua Weng; Karolynn Siegel; Ali G Gharavi; Wendy K Chung
Journal:  Genet Med       Date:  2019-04-01       Impact factor: 8.864

7.  Factors Predicting Participation in the Prospective Genomic Sequencing Study, Total Cancer Care (TCC), in Kentucky.

Authors:  McKayla J Riggs; Bin Huang; Quan Chen; Therese Bocklage; Marissa R Schuh; Ming Poi; John L Villano; Michael J Cavnar; Susanne M Arnold; Rachel W Miller; Frederick R Ueland; Jill M Kolesar
Journal:  J Rural Health       Date:  2020-07-06       Impact factor: 5.667

8.  Polygenic risk scores in the clinic: new perspectives needed on familiar ethical issues.

Authors:  Anna C F Lewis; Robert C Green
Journal:  Genome Med       Date:  2021-01-28       Impact factor: 11.117

9.  Patient-Reported Outcomes and Experiences with Population Genetic Testing Offered Through a Primary Care Network.

Authors:  Amy A Lemke; Laura M Amendola; Jennifer Thompson; Henry M Dunnenberger; Kristine Kuchta; Chi Wang; Kristen Dilzell-Yu; Peter J Hulick
Journal:  Genet Test Mol Biomarkers       Date:  2021-02

10.  Factors Associated with Declining to Participate in a Pediatric Oncology Next Generation Sequencing Study.

Authors:  Katianne M Howard Sharp; Niki Jurbergs; Annastasia Ouma; Lynn Harrison; Elsie Gerhardt; Leslie Taylor; Kayla Hamilton; Rose B McGee; Regina Nuccio; Emily Quinn; Stacy Hines-Dowell; Chimene Kesserwan; Anusha Sunkara; Jami S Gattuso; Michelle Pritchard; Belinda Mandrell; Mary V Relling; Cyrine E Haidar; Guolian Kang; Liza M Johnson; Kim E Nichols
Journal:  JCO Precis Oncol       Date:  2020-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.